Meeting
2020 ASCO Virtual Scientific Program
Study of anlotinib combined with icotinib as the first-line treatment in non-small cell lung cancer (NSCLC) patients harboring activating EGFR mutations (ALTER-L004).
Presenter
Dingzhi Huang
Tianjin Medical University Cancer Institute and Hospital
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT03736837
Citation
J Clin Oncol 38: 2020 (suppl; abstr 9573)
DOI
10.1200/JCO.2020.38.15_suppl.9573
Abstract #
9573
Poster Bd #
339
Abstract Disclosures
Similar Videos & Slides
Speaker: Panel Discussion
Videos & Slides
2011 ASCO Annual Meeting
Epidermal growth factor receptor (EGFR) mutation testing and first-line treatment with gefitinib as a strategy in the treatment of patients with advanced non-small cell lung cancer (NSCLC).
Speaker: Gilberto Lopes, MD, MBA, FASCO
Speaker: James M. Rae, MD
Videos & Slides
2024 ASCO Annual Meeting
REZILIENT2: Phase 2 study of zipalertinib in patients with advanced non-small cell lung cancer (NSCLC) with exon 20 insertions (ex20ins) and other uncommon epidermal growth factor receptor (EGFR) mutations.
Speaker: Helena Alexandra Yu, MD